January 31, 2017 News by Patricia Silva, PhD Patient Opinions on Zinbryta Seen to Match Phase 3 Trial Data, Supporting Questionnaire Use More relapsing multiple sclerosis (MS) patients treated withĀ Zinbryta (daclizumab)Ā said they feltĀ itsĀ health benefitsĀ than did thoseĀ givenĀ Avonex (interferon beta-1a) ā demonstrating that patient-reported outcomes do mirror objective measures of improved health in a clinical trial ofĀ the two drugs. Patient-reported changesĀ in both physical and psychological health contribute to a more comprehensive picture of…
January 19, 2017 News by Patricia Silva, PhD Siemens Healthineers and Biogen to Enhance MRI’s Ability to Help MS Patients Siemens Healthineers and BiogenĀ will collaborate to develop new magnetic resonance imaging (MRI) applications that can quantify key markers of multiple sclerosis (MS). āBy bringing together the shared expertise of both Siemens Healthineers and Biogen in imaging and neurology, respectively, we seek to develop new measurement tools that…
January 11, 2017 Columns by Laura Kolaczkowski MS PATHS: Be Aware of the Info You Share Would you open your bank account and write a blank check to just anyone requesting something of value from you? Of course not. So, why would we do that with our healthcare information? I was recently sent an informed consent form from the MS clinic where I am treated,…
October 5, 2016 News by Patricia Silva, PhD MS Trust to Oppose NICE Plan to Reject Zinbryta as MS Therapy in Health System for England, Wales The Multiple Sclerosis (MS) Trust isĀ expressing its disappointment at the recent committee decision ofĀ theĀ National Institute for Health and Care ExcellenceĀ (NICE)Ā to not recommendĀ Zinbryta (daclizumab) be made available as a therapy to MSĀ patients using the public health system in England and Wales. NICE’sĀ preliminary recommendationĀ was based on a review of…
October 4, 2016 News by Patricia Silva, PhD NICE Planning to Reject MS Treatment, Zinbryta, in England and Wales TheĀ National Institute for Health and Care Excellence (NICE), the health authorityĀ for England and Wales,Ā has decided not to recommend Zinbryta (daclizumab)Ā be made available to multiple sclerosis (MS)Ā patients through the country’s health service. The decision came in a first stage of the drugās review process, and NICE is welcoming…
September 19, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Biogen and AbbVie Present New Positive Data on Zinbryta to Treat Relapsing MS BiogenĀ andĀ AbbVieĀ presented positive new post-hoc analysis from the pivotal DECIDE clinical trial, whichĀ showed that a significantly larger number of relapsing multiple sclerosis (RMS) patients treated with Zinbryta (daclizumab) hadĀ no evidence of disease activity (NEDA)Ā compared to thoseĀ treated with Avonex (interferon beta-1a).Ā The data wereĀ given at the recentĀ 32nd Congress of the European…
September 12, 2016 News by Patricia Silva, PhD #ECTRIMS2016 – Biogen to Unveil Study into Economic and Human Costs of MS At theĀ European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2016 Congress, taking placeĀ inĀ London on Sept. 14ā17, Biogen will present the Multiple Sclerosis Cost of Illness study, based on research intoĀ more than 16,000 MS patients throughout Europe. The study builds on data from a leading 2005 study that…
July 7, 2016 News by Patricia Inacio, PhD Zinbryta (Daclizumab) Approved in Europe to Treat Relapsing MS Biogen and AbbVieĀ announced that the drug ZinbrytaĀ (daclizumab) has received marketing authorization by the European Commission, and is an approved treatment across most ofĀ Europe forĀ adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a self-administered, once monthly subcutaneous injection. āClinical data showed Zinbryta significantly reduced relapses, 24-week…
June 2, 2016 News by Ćzge Ćzkaya, PhD MS Drug Tysabri (Natalizumab) Gets Positive Opinion from European Medicines Agency Biogen, announced that TYSABRI, a drug developed to treat people with multiple sclerosis (MS) has received a positive opinion from the European Medicine Agency (EMA) recommending its approval to be used in people with elapsing-remitting multiple sclerosis (RRMS).
May 31, 2016 News by Patricia Silva, PhD Multiple Sclerosis treatment Zinbryta (Daclizumab) Approved by FDA Zinbryta (daclizumab) was approved May 27 for the treatment of adults with relapsing multiple sclerosis (MS). The U.S. Food and Drug Administration (FDA) cleared Biogenās new long-acting injection as a patient self-administered monthly therapy. The director of Neurology Products at the U.S. FDAās Center for Drug Evaluation…
May 4, 2016 News by Patricia Silva, PhD CHMP Favors European Approval of Zinbryta (Daclizumab) to Treat Relapsing MS The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recently recommended marketing authorization to Zinbryta (daclizumab) for the treatment of patients with relapsing multiple sclerosis (RMS). Zinbryta (daclizumabĀ HYP) is a humanized monoclonal antibody that is injected every four weeks, and being developed by…
April 22, 2016 News by Patricia Silva, PhD Biogen and AbbVie Present New Data Showing Zinbryta, an RRMS Drug Candidate, Aids Cognition Without Immune Depletion New data presented byĀ BiogenĀ andĀ AbbVieĀ at the recent 68th annual meeting of theĀ American Academy of Neurology (AAN) showed that ZinbrytaĀ (daclizumab high-yield process) improved cognitive outcome measures in patients with relapsing forms of multiple sclerosis (RMS). Additional results ā from post-hoc analyses of clinicalĀ trials ā also offer a better…
April 20, 2016 News by admin Biogen Releases New Data Showing Effectiveness of Tecfidera in Newly Diagnosed MS Patients at AAN 2016 BiogenĀ reported new data describing the effectiveness of TecfideraĀ (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients in a recent presentation at the 68th annual meeting of the American Academy of Neurology (AAN). The conference, taking placeĀ in Vancouver, Canada, runs through April 21. Tecfidera is an…
April 14, 2016 News by admin Array of Multiple Sclerosis Trial Data to Be Presented by Biogen at 2016 AAN Meeting A rangeĀ of new multiple sclerosis (MS) data from Biogen will be revealedĀ atĀ the 68th annual meeting of the American Academy of Neurology (AAN) in Vancouver, Canada, on April 15ā21. Presentations will include studies on TecfideraĀ (dimethyl fumarate),Ā one of the most frequently usedĀ oral MS treatments worldwide, as well as several other…
March 9, 2016 News by Patricia Silva, PhD #MySupportHero Program Celebrates MS Caregivers in All Walks of Life To celebrate the many family, friends, healthcare professionals, and advocacy communities offeringĀ vitalĀ support to people living with multiple sclerosis (MS)Ā day after day,Ā MSWorld and Biogen have created the #MySupportHero program. The social media campaignĀ runs through March, MS Awareness Month, to allowĀ people with MS toĀ thank all those who encourage and…
February 25, 2016 News by Margarida Azevedo, MSc Biogen’s ‘1MSg Campaign’ Encourages MS Patients to Better Manage Their Disease, Engage with Specialists BiogenĀ is launching an initiative developed with the assistance of clinical experts ā the 1MSg campaignĀ āĀ to educate and encourage multiple sclerosis (MS) patients to make disease management decisions that are well-informed andĀ basedĀ onĀ the latest scientific research. The campaignās motto is āTake control, known your choices,ā and one of its main…
January 29, 2016 News by Charles Moore Multiple Sclerosis Patient and ‘Sopranos’ Actress Takes MS Struggle Public Millions of television viewers who watchedĀ the popularĀ HBO mob drama series “The Sopranos”Ā saw actress Jamie Lynn Sigler grow from a teen into a young woman as Meadow Soprano, theĀ independent-minded daughter of mafia boss Tony Soprano, played by the late James Gandolfini. This week, Sigler revealed she has been battling multiple…
January 29, 2016 News by Patricia Silva, PhD Guidelines Issued for Monitoring of MS Patients on Natalizumab Treatment A panel of neurologists from the U.K. and Ireland recently developed practical consensus guidelines for monitoring multiple sclerosis (MS) patients on natalizumab (Tysabri)Ā therapy for the risk of developing progressive multifocal leukoencephalopathy (PML), a life-threatening viral infection caused by the John Cunningham (JC) virus. The panel was summoned by…
January 19, 2016 News by admin Anti-LINGO-1: All You Need to Know Recently, Biogen released results from its Phase 2 acute optic neuritis (AON) RENEW trial which tested Anti-LINGO-1. Learn more about this results here. So what isĀ Anti-LINGO-1? According to the MS Society,Ā Anti-LINGO-1 (also known as BIIB033) is a treatment in development by the pharmaceutical company Biogen which is currently…
October 22, 2015 News by Margarida Azevedo, MSc Biogen’s TYSABRI for Secondary Progressive MS Fails to Meet Phase 3 Trial Endpoints Biogen Inc. recently reported that the Phase 3 ASCEND clinical trial study testing TYSABRI efficacy in patients with secondary progressive multiple sclerosis (SPMS) did not achieve its primary and secondary goals. According to the company, the comprehensive results of the study will be revealed at a future medical conference.
October 22, 2015 News by Patricia Silva, PhD Biogen’s Investment in Multiple Sclerosis Therapies Reinforced in Company Restructuring Advancing key medicinal treatments likeĀ TECFIDERA (dimethyl fumarate), the most prescribed oral treatment for multiple sclerosis (MS), is a key focus of a company-wide restructuring recently announced byĀ Biogen, Inc.Ā TECFIDERA has been shown to reduce relapse rates, slow disability progression and the number of brain lesions in patients with relapsing forms…
October 9, 2015 News by Margarida Azevedo, MSc Promising Data on ZINBRYTA (Daclizumab High-Yield Process) Compared to Interferon Beta-1a in RRMS, ECTRIMS 2015 Lead scientists representing Biogen and AbbVie presented new data on clinical results from the Phase 3 study DECIDE on the compound ZINBRYTA TM at the 31st Congress of the European Committee for Treatment and Research in MS (ECTRIMS) in Barcelona, Spain. The full results of the 2 to 3-year long…
October 9, 2015 News by Patricia Silva, PhD EXCLUSIVE: Top MS Researcher Gives Interview With MS News Today After Presenting New Data on Biogen’s TECFIDERA at #ECTRIMS2015 A top MS researcher for Biogen Idec answered questions in an exclusive interview with Multiple Sclerosis News Today correspondent Dr. Ana de Barros at a Satellite Symposia entitled āMS developments: transitioning evidence into clinical practiceā presentedĀ by the companyĀ this morning at the 31st Congress of the European Committee for Treatment and…
October 2, 2015 News by Patricia Silva, PhD Biogen to Present New Data at Upcoming ECTRIMS 2015 Congress on MS Therapies, Including TECFIDERA Biogen, a biotechnology company focused on innovative therapies for autoimmune disorders, neurodegenerative diseases and hematological conditions, recently announced that it will present new data on its multiple sclerosis (MS) portfolio of therapeutic agents at the upcoming 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis…
September 10, 2015 News by Patricia Silva, PhD Biogen Obtains Exclusive Rights Over Promising MT-1303 Drug for Autoimmune Diseases, Multiple Sclerosis BiogenĀ recently announced an agreement with Mitsubishi Tanabe Pharma Corporation (MTPC), a research-driven pharmaceutical company based in Japan, to exclusively license the companyās experimental product MT-1303. The product is a late stage experimental oral compound developed as a therapy for several autoimmune conditions. MT-1303 is a sphingosine 1-phosphate (S1P)…
July 27, 2015 News by Charles Moore Biogen’s Tecfidera Now The Most Prescribed Oral MS Therapy Globally Cambridge, Massachusetts based Biogen Inc. has reported its second quarter 2015 results, posting a year-over-year seven percent revenue increase to $2.6 Billion in the quarter. āBiogen remains focused on improving the lives of people living with complex diseases,ā says Chief Executive Officer George A. Scangos, Ph.D. āTecfidera, which is now…
July 13, 2015 News by Patricia Silva, PhD New MS Study Shows TYSABRI Improves Cognitive Impairment Researchers at Spedali Civili of Brescia in Italy recently published findings in the journal PLoS OneĀ that Biogen’s Tysabri (natalizumab) can improve cognitive impairment in patients with relapsing remitting multiple sclerosis (RRMS) over the course ofĀ at least three years. The study is entitled āNatalizumab Significantly…
June 19, 2015 News by Kara Elam Biogen and SELF Join Together to Help Women With Relapsing Multiple Sclerosis Re-imagine Daily Life Biogen, a global biotechnology company with over 30 years of clinical excellence in Multiple Sclerosis (MS) research, has recently announced the launch of Reimagine MySelf, a blog dedicated to helping women navigate their daily lives while also dealing with the complications that come with a diagnosis of relapsing MS…
May 6, 2015 News by Patricia Silva, PhD FDA Evaluates ZINBRYTA For MS Treatment The U.S. Food and Drug Administration (FDA) has announced it willĀ considerĀ marketing approval ofĀ ZINBRYTA (daclizumab high-yield process), a potential treatment for relapsing forms of multiple sclerosis (MS). Biogen and AbbVie, who are jointly developing the therapy, have filed aĀ Biologics License Application…
April 22, 2015 News by Patricia Silva, PhD Biogen To Present Data On The Effectiveness of TECFIDERA In Newly-Diagnosed MS Patients During The ANN Annual Meeting BiogenĀ hasĀ recently announced novelĀ results to support the effectiveness of TECFIDERAĀ (dimethyl fumarate) inĀ the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). The results revealed that TECFIDERA significantly reduced disability progression andĀ relapses in RRMS patients who received their diagnosis for the first time and had a highly active form of the disease.Ā TECFIDERA…